Journal Lancet - Gastroenterology and Hepatology

Targeting the EGFR signalling pathway in metastatic colorectal cancer

S Napolitano , G Martini , D Ciardiello , ... , F Ciardiello

10.1016/s2468-1253(23)00479-x

Progress is impossible without change: understanding the evolving nomenclature of steatotic liver disease and its effect on hepatology practice.

PN Brennan , OD Tavabie , W Li , ... , KWM Abeysekera

10.1016/s2468-1253(23)00453-3

A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARBIS): a single-centre, single-blind, randomised controlled trial

S Nybacka , H Törnblom , A Josefsson , ... , M Simrén

10.1016/s2468-1253(24)00045-1

Pathophysiology and therapeutic options for cirrhotic portal hypertension

S Guixé-Muntet , S Quesada-Vázquez , J Gracia-Sancho

10.1016/s2468-1253(23)00438-7

Liver transplantation for acute-on-chronic liver failure

F Artru , F Trovato , M Morrison , ... , M McPhail

10.1016/s2468-1253(23)00363-1

Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial

N Ovchinsky , M Aumar , A Baker , ... , JP Mattsson

10.1016/s2468-1253(24)00074-8

Rethinking colorectal cancer prognosis: beyond microsatellite status

E Fenocchio

10.1016/s2468-1253(24)00129-8

Clinical significance of combined tumour-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: a systematic review and network meta-analysis

D Wankhede , T Yuan , M Kloor , ... , M Hoffmeister

10.1016/s2468-1253(24)00091-8

Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

AG Miethke , A Moukarzel , G Porta , ... , RJ Thompson

10.1016/s2468-1253(24)00080-3

Managing irritable bowel syndrome: balancing diet and pharmacotherapy

UC Ghoshal , U Mustafa , MK Goenka

10.1016/s2468-1253(24)00113-4